- Home
- KNF vs ACAD Comparison
KNF vs ACAD Comparison
Compare KNF & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNF
- ACAD
- Stock Information
- Founded
- KNF 1917
- ACAD 1993
- Country
- KNF United States
- ACAD United States
- Employees
- KNF N/A
- ACAD N/A
- Industry
- KNF
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- KNF
- ACAD Health Care
- Exchange
- KNF Nasdaq
- ACAD Nasdaq
- Market Cap
- KNF 4.6B
- ACAD 4.3B
- IPO Year
- KNF N/A
- ACAD 2004
- Fundamental
- Price
- KNF $77.96
- ACAD $23.61
- Analyst Decision
- KNF Strong Buy
- ACAD Buy
- Analyst Count
- KNF 6
- ACAD 21
- Target Price
- KNF $114.33
- ACAD $29.30
- AVG Volume (30 Days)
- KNF 625.5K
- ACAD 1.9M
- Earning Date
- KNF 11-03-2025
- ACAD 11-05-2025
- Dividend Yield
- KNF N/A
- ACAD N/A
- EPS Growth
- KNF N/A
- ACAD 615.00
- EPS
- KNF 2.71
- ACAD 1.33
- Revenue
- KNF $2,949,740,000.00
- ACAD $1,018,885,000.00
- Revenue This Year
- KNF $11.80
- ACAD $14.01
- Revenue Next Year
- KNF $5.95
- ACAD $11.72
- P/E Ratio
- KNF $28.82
- ACAD $17.81
- Revenue Growth
- KNF 2.64
- ACAD 14.41
- 52 Week Low
- KNF $74.51
- ACAD $13.40
- 52 Week High
- KNF $108.83
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- KNF 39.51
- ACAD 39.78
- Support Level
- KNF $77.46
- ACAD $23.70
- Resistance Level
- KNF $81.72
- ACAD $25.90
- Average True Range (ATR)
- KNF 2.75
- ACAD 0.74
- MACD
- KNF -0.60
- ACAD -0.33
- Stochastic Oscillator
- KNF 11.71
- ACAD 8.16
About KNF Knife Riv Holding Co.
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. Its segments include Pacific, Northwest, Mountain, North Central, South, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.